Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Almasa Bass"'
Autor:
Yushi Inoue, Somsak Tiamkao, Dong Zhou, Leonor Cabral‐Lim, Kheng Seang Lim, Shih‐Hui Lim, Jing‐Jane Tsai, Brian Moseley, Lin Wang, Weiwei Sun, Yoshinobu Hayakawa, Hiroshi Sasamoto, Tomonobu Sano, Carrie McClung, Almasa Bass
Publikováno v:
Epilepsia Open, Vol 9, Iss 3, Pp 1007-1020 (2024)
Abstract Objective Evaluate efficacy, safety, and tolerability of adjunctive brivaracetam (BRV) in adult Asian patients with focal‐onset seizures (FOS). Methods Phase III, randomized, double‐blind, placebo‐controlled study (EP0083; NCT03083665)
Externí odkaz:
https://doaj.org/article/e7ed2c29822d4dacbc5c2390b953108b
Autor:
Arnold J. Weil, Elizabeth T. Masters, Alexandra I. Barsdorf, Almasa Bass, Glenn Pixton, Jacquelyn G. Wilson, Gernot Wolfram
Publikováno v:
Health and Quality of Life Outcomes, Vol 15, Iss 1, Pp 1-7 (2017)
Abstract Background The efficacy of ALO-02, an abuse-deterrent formulation containing extended-release oxycodone and sequestered naltrexone, in the treatment of chronic low back pain (CLBP) was studied in a 12-week randomized controlled trial. Primar
Externí odkaz:
https://doaj.org/article/918dccc8e1d545fa9ea04368d35bc05b
Publikováno v:
Therapeutic Advances in Drug Safety, Vol 10 (2019)
Background: Abuse of prescription opioids, particularly by intravenous (IV) administration, can cause respiratory depression and death. ALO-02, an abuse-deterrent opioid formulation, is designed to release sequestered naltrexone upon manipulation by
Externí odkaz:
https://doaj.org/article/e4280abc13a748d0adc00eb6928d629e
Autor:
Gernot Wolfram, Gary G. Wilson, Almasa Bass, Glenn C. Pixton, Richard Rauck, Bimal Malhotra, Jacquelyn G Wilson, Joseph Gimbel
Publikováno v:
Journal of Opioid Management. 15:417-427
Objective: To evaluate the clinical effects of naltrexone following ALO-02 administration. Design: Two phase three studies: an open-label, single-arm safety study, and a double-blind, placebo-controlled, randomized withdrawal, efficacy study (Clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdd0d33293d918ce0f93832824b02091
https://doi.org/10.5055/jom.2019.0530
https://doi.org/10.5055/jom.2019.0530
Autor:
Almasa Bass, Kathleen Pelletier, Hua Wei, Susan Zhou, Anne Hickman, Haihong Shi, Rajesh Krishna, Steven G. Terra, Vaishali Sahasrabudhe, Kyle Matschke, Daryl J. Fediuk, Yali Liang
Publikováno v:
Clinical Pharmacology in Drug Development
A fixed‐dose combination (FDC) of ertugliflozin, a selective sodium‐glucose cotransporter 2 inhibitor, and immediate‐release metformin is approved for the treatment of type 2 diabetes mellitus in the United States and European Union. Four open
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b8329aa2850321c30b13667030b7e6b
https://doi.org/10.1002/cpdd.703
https://doi.org/10.1002/cpdd.703
Autor:
Haihong Shi, Vikas Kumar Dawra, Almasa Bass, Anne Hickman, Susan Zhou, Yali Liang, David L. Cutler, Steven G. Terra, Vaishali Sahasrabudhe
Publikováno v:
International Journal of Clinical Pharmacology and Therapeutics
Objective Ertugliflozin is approved in the US and European Union as a stand-alone product for adults with type 2 diabetes mellitus as once daily (QD) dosing. The approved fixed-dose combination (FDC) of ertugliflozin and immediate-release metformin i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37b4984e112db0b7438a4f3bc3b713b0
https://doi.org/10.5414/cp203343
https://doi.org/10.5414/cp203343
Publikováno v:
Open Forum Infectious Diseases
Background For new antibiotics developed to treat antibiotic-resistant Gram-negative infections, the US Food and Drug Administration (FDA) regulatory pathway includes complicated urinary tract infection (cUTI) clinical trials in which the clinical is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f487807f37c49b1bd2353b77395887e
http://europepmc.org/articles/PMC7953653
http://europepmc.org/articles/PMC7953653
Publikováno v:
Current medical research and opinion. 36(1)
Objective: To assess the impact of age on the safety and tolerability of ALO-02, an abuse-deterrent opioid formulation consisting of oxycodone hydrochloride and sequestered naltrexone hydrochloride...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::072d5efecff6e3f4fb63f1163dcfcf9b
https://pubmed.ncbi.nlm.nih.gov/31456431
https://pubmed.ncbi.nlm.nih.gov/31456431
Autor:
Almasa, Bass, Anna, Plotka, Khurshid, Mridha, Catherine, Sattler, Albert M, Kim, David R, Plowchalk
Publikováno v:
Health Science Reports
Aim Prior to the discontinuation of bococizumab's clinical development, it was considered advantageous to develop an infrequent dosing regimen (eg, monthly). Therefore, we conducted a phase 1 study to evaluate the pharmacokinetics, pharmacodynamics,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::05320977192c803d72c2d3046c333112
https://pubmed.ncbi.nlm.nih.gov/30623096
https://pubmed.ncbi.nlm.nih.gov/30623096
Autor:
Jacquelyn G Wilson, Beatrice Setnik, Kenneth W. Sommerville, Glenn C. Pixton, Martin E. Hale, Candace Bramson, Almasa Bass, Paul Meisner, Richard L Rauck, Bimal Malhotra, Gernot Wolfram
Publikováno v:
Pain. 156:1660-1669
The objective of this multicenter, double-blind, placebo-controlled, randomized withdrawal study was to evaluate the efficacy and safety of ALO-02, an abuse-deterrent formulation containing pellets of extended-release oxycodone hydrochloride (HCl) su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2694b71e8acf84f6d1eb475187601c0
https://doi.org/10.1097/j.pain.0000000000000230
https://doi.org/10.1097/j.pain.0000000000000230